These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 27749545)

  • 1. The influence of a gene expression signature on the diagnosis and recommended treatment of melanocytic tumors by dermatopathologists.
    Cockerell CJ; Tschen J; Evans B; Bess E; Kidd J; Kolquist KA; Rock C; Clarke LE
    Medicine (Baltimore); 2016 Oct; 95(40):e4887. PubMed ID: 27749545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes.
    Ko JS; Matharoo-Ball B; Billings SD; Thomson BJ; Tang JY; Sarin KY; Cai E; Kim J; Rock C; Kimbrell HZ; Flake DD; Warf MB; Nelson J; Davis T; Miller C; Rushton K; Hartman AR; Wenstrup RJ; Clarke LE
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1107-1113. PubMed ID: 28377414
    [No Abstract]   [Full Text] [Related]  

  • 3. An independent validation of a gene expression signature to differentiate malignant melanoma from benign melanocytic nevi.
    Clarke LE; Flake DD; Busam K; Cockerell C; Helm K; McNiff J; Reed J; Tschen J; Kim J; Barnhill R; Elenitsas R; Prieto VG; Nelson J; Kimbrell H; Kolquist KA; Brown KL; Warf MB; Roa BB; Wenstrup RJ
    Cancer; 2017 Feb; 123(4):617-628. PubMed ID: 27768230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation indices correlate with diagnosis and metastasis in diagnostically challenging melanocytic tumors.
    Al-Rohil RN; Curry JL; Torres-Cabala CA; Nagarajan P; Ivan D; Aung PP; Lyons GF; Bassett RL; Prieto VG; Tetzlaff MT
    Hum Pathol; 2016 Jul; 53():73-81. PubMed ID: 27004944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma.
    Clarke LE; Warf MB; Flake DD; Hartman AR; Tahan S; Shea CR; Gerami P; Messina J; Florell SR; Wenstrup RJ; Rushton K; Roundy KM; Rock C; Roa B; Kolquist KA; Gutin A; Billings S; Leachman S
    J Cutan Pathol; 2015 Apr; 42(4):244-52. PubMed ID: 25727210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression signature as an ancillary method in the diagnosis of desmoplastic melanoma.
    Clarke LE; Pimentel JD; Zalaznick H; Wang L; Busam KJ
    Hum Pathol; 2017 Dec; 70():113-120. PubMed ID: 29079183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordance Analysis of the 23-Gene Expression Signature (myPath Melanoma) With Fluorescence In Situ Hybridization Assay and Single Nucleotide Polymorphism Array in the Analysis of Challenging Melanocytic Lesions: Results From an Academic Medical Center.
    Castillo SA; Pham AK; Dagrosa AT; Yan S; Barton DT; Lefferts JA; Linos K
    Am J Dermatopathol; 2020 Dec; 42(12):939-947. PubMed ID: 32675469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions.
    Ko JS; Clarke LE; Minca EC; Brown K; Flake DD; Billings SD
    Hum Pathol; 2019 Apr; 86():213-221. PubMed ID: 30566894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'?
    Braun RP; Gutkowicz-Krusin D; Rabinovitz H; Cognetta A; Hofmann-Wellenhof R; Ahlgrimm-Siess V; Polsky D; Oliviero M; Kolm I; Googe P; King R; Prieto VG; French L; Marghoob A; Mihm M
    Dermatology; 2012; 224(1):51-8. PubMed ID: 22433231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic discordance among histopathological reviewers of melanocytic lesions.
    Hosler GA; Goldberg MS; Estrada SI; O'Neil B; Amin SM; Plaza JA
    J Cutan Pathol; 2024 Aug; 51(8):624-633. PubMed ID: 38725224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporation of dermoscopy improves inter-observer agreement among dermatopathologists in histologic assessment of melanocytic neoplasms.
    Shi K; Compres E; Walton KE; Mohan LS; Zhang B; Panah E; Quan VL; Garfield EM; Khan AU; Kim D; Yazdan P; Robinson JK; Gerami P
    Arch Dermatol Res; 2021 Mar; 313(2):101-108. PubMed ID: 32338293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Second-Opinion Strategies for Diagnoses of Cutaneous Melanocytic Lesions.
    Piepkorn MW; Longton GM; Reisch LM; Elder DE; Pepe MS; Kerr KF; Tosteson ANA; Nelson HD; Knezevich S; Radick A; Shucard H; Onega T; Carney PA; Elmore JG; Barnhill RL
    JAMA Netw Open; 2019 Oct; 2(10):e1912597. PubMed ID: 31603483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of a gene-expression signature on the treatment of diagnostically challenging melanocytic lesions.
    Cockerell C; Tschen J; Billings SD; Evans B; Brown K; Rock C; Clarke LE
    Per Med; 2017 Mar; 14(2):123-130. PubMed ID: 28757886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.
    Conway K; Edmiston SN; Parker JS; Kuan PF; Tsai YH; Groben PA; Zedek DC; Scott GA; Parrish EA; Hao H; Pearlstein MV; Frank JS; Carson CC; Wilkerson MD; Zhao X; Slater NA; Moschos SJ; Ollila DW; Thomas NE
    J Invest Dermatol; 2019 Jun; 139(6):1349-1361. PubMed ID: 30529013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
    Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
    Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions.
    Mudhar HS; Milman T; Stevenson S; Watson M; Kim J; Magan T; Salvi SM; Harley U; Lally SE; Shields CL
    Hum Pathol; 2023 Apr; 134():1-18. PubMed ID: 36804828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.
    Lezcano C; Jungbluth AA; Busam KJ
    Am J Surg Pathol; 2020 Jul; 44(7):893-900. PubMed ID: 32317605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validity of a gene expression signature in diagnostically uncertain neoplasms.
    Clarke LE; Mabey B; Flake Ii DD; Meek S; Cassarino DS; Duncan LM; High WA; Napekoski KM; Prieto VG; Tetzlaff MT; Vitale P; Elder DE
    Per Med; 2020 Sep; 17(5):361-371. PubMed ID: 32915688
    [No Abstract]   [Full Text] [Related]  

  • 19. Translation of a circulating miRNA signature of melanoma into a solid tissue assay to improve diagnostic accuracy and precision.
    Laar RV; King S; McCoy R; Saad M; Fereday S; Winship I; Uzzell C; Landgren A
    Biomark Med; 2021 Sep; 15(13):1111-1122. PubMed ID: 34184547
    [No Abstract]   [Full Text] [Related]  

  • 20. Association of Clinical, Dermoscopic, and Histopathologic Findings With Gene Expression in Patients With Balloon Cell Melanoma.
    Friedman BJ; Stoner R; Sahu J; Lee JB
    JAMA Dermatol; 2018 Jan; 154(1):77-81. PubMed ID: 29238799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.